ENSG vs. MDLN: Ensign vs. Medline Stock Comparison

Company Profile

Ensign (ENSG) and Medline (MDLN) both fall under the Health Care Equipment & Services industry group, but ENSG is classified in Health Care Providers & Services while MDLN is classified in Health Care Equipment & Supplies.

Ensign (ENSG) has been public since November 9, 2007 with a meaningfully longer listed history, while Medline (MDLN) only listed on December 17, 2025 — long-window metrics on the MDLN side should be interpreted with caution.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Ensign (ENSG) has a non-negative beta of 0.65.

Risk-Adjusted Performance

Risk-Return Positioning

Both ENSG and MDLN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Ensign (ENSG) at 17.05% sits in the top ROE quartile, while Medline (MDLN) at 4.85% is closer to the peer norm — stronger capital efficiency for ENSG.

Both Ensign (ENSG) at 7.03% and Medline (MDLN) at 1.85% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Both Ensign (ENSG) at 9.23% and Medline (MDLN) at 5.22% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Ensign (ENSG) reports revenue growth of 18.72%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Medline (MDLN) at 117.38% clears its industry range for EPS growth, a much stronger earnings trajectory than Ensign (ENSG) at 14.06%, which is closer to a typical peer reading.

Growth Metrics

Financial Strength

Medline (MDLN) at 4.04 carries current ratio above its industry’s typical mid-range, while Ensign (ENSG) at 1.20 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Ensign (ENSG) at 0.89 and Medline (MDLN) at 0.65 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Medline (MDLN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Ensign (ENSG) reports a yield of 0.14%, ranking against industry peers normally.

Medline (MDLN) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Ensign (ENSG) reports a payout of 3.87%, ranking against industry peers normally.

Dividend Metrics

Valuation

Ensign (ENSG) at 26.95 is near its industry’s usual P/E ratio, while Medline (MDLN) at 90.09 sits above its peer range — an unusually expensive price for MDLN’s trailing earnings.

On P/S ratio, both Ensign (ENSG) at 1.86 and Medline (MDLN) at 1.70 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

On P/B ratio, both Ensign (ENSG) at 4.09 and Medline (MDLN) at 2.95 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics